ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combination with anti-VEGF (ranibizumab) for treatment of Diabetic Macular Edema (DME)

    NEXT STORY
    Sanofi: First-quarter 2018 Business EPS(1) up 1.4% at CER
    PREV STORY
    TiGenix: Publication of prospectus and response memorandum for Takeda takeover bid commencing on April 30, 2018
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    VBL Therapeutics Announces the Appointments of Susan Kelley and David Hastings to Its Board of Directors

    Senior pharmaceutical executives with extensive experience in immuno-oncology, drug development, commercializing oncology medications and ...

    author_avatar
    NASDAQ Market News

    EyePoint Pharmaceuticals Signs Exclusive License Agreement with Equinox Science to Develop Tyrosine Kinase Inhibitor Vorolanib for the Treatment of Wet AMD, Diabetic Retinopathy and Retinal Vein Occlusion

    author_avatar
    NASDAQ Market News

    Eloxx Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Society of Nephrology (ASN) Kidney Week 2019

    author_avatar
    NASDAQ Market News